Skip to main content
HARBIN GLORIA PHARMACEUTICALS Co., LTD logo

HARBIN GLORIA PHARMACEUTICALS Co., LTD — Investor Relations & Filings

Ticker · 002437 ISIN · CNE100000QG8 LEI · 300300K1ZDAXM6M73U33 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,133 across all filing types
Latest filing 2025-08-26 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 002437

About HARBIN GLORIA PHARMACEUTICALS Co., LTD

https://www.gloria.cc

Harbin Gloria Pharmaceuticals Co., Ltd. focuses on the research, development, manufacturing, and commercialization of diverse pharmaceutical products. The company specializes in therapeutic areas including cardiovascular and cerebrovascular diseases, orthopedics, oncology, and metabolic disorders. Its portfolio comprises chemical drugs, biological products, and specialized injections, with key products such as Alprostadil and Deer Melon Polypeptide. The organization prioritizes technological innovation through a dedicated R&D infrastructure aimed at developing both generic and innovative medications. It maintains multiple production facilities and an extensive distribution network to supply healthcare solutions for chronic and acute conditions.

Recent filings

Filing Released Lang Actions
股东会议事规则（2025年8月）
Governance Information Classification · 95% confidence The document is titled as "哈尔滨誉衡药业股份有限公司 股东会议事规则" which translates to "Harbin Yuheng Pharmaceutical Co., Ltd. Shareholders Meeting Rules." The content extensively details the rules and procedures for convening, notifying, and conducting shareholders' meetings, including voting procedures, proposal submissions, and legal compliance. It does not contain financial statements, audit opinions, or earnings data. It is a governance document outlining internal rules for shareholder meetings rather than a report of financial results or an announcement. Therefore, it fits best under Governance Information (CGR). The document length (7823 characters) and detailed procedural content support this classification with high confidence.
2025-08-26 Chinese
总经理（经理层）工作细则（2025年8月）
Governance Information Classification · 95% confidence The document is titled as '哈尔滨誉衡药业股份有限公司 总经理（经理层）工作细则', which translates to 'Harbin Yuheng Pharmaceutical Co., Ltd. General Manager (Management) Work Rules'. The content details the duties, responsibilities, authority, reporting, and performance evaluation of the company's general manager and senior management personnel. It includes internal governance rules and procedures for management conduct, decision-making, and reporting to the board. There is no financial data, no audit information, no voting results, no earnings or capital updates, no legal proceedings, no merger or acquisition information, and no shareholder transactions. The document is a governance-related internal regulation about management roles and responsibilities. Therefore, it fits best under Governance Information (CGR). The document length is 5696 characters, which is sufficient for a detailed governance report, not a mere announcement or certification. Hence, the classification is CGR with high confidence.
2025-08-26 Chinese
投资者关系管理制度（2025年8月）
Governance Information Classification · 95% confidence The document is titled '投资者关系管理制度' which translates to 'Investor Relations Management System'. It outlines the company's policies and procedures for managing investor relations, including communication principles, methods, organizational responsibilities, and compliance with relevant laws and regulations. There are no financial statements, earnings data, audit opinions, or meeting results presented. The document is a governance-related policy document detailing internal rules and practices for investor relations management. It does not fit categories like Annual Report, Earnings Release, or Call Transcript. It aligns best with Governance Information (CGR) as it details governance practices related to investor relations management.
2025-08-26 Chinese
内幕信息知情人管理制度（2025年8月）
Regulatory Filings Classification · 95% confidence The document is a detailed internal management system for insider information at Harbin Yuheng Pharmaceutical Co., Ltd. It includes definitions of insider information, the scope of insider personnel, management procedures, confidentiality obligations, and responsibility accountability. It also contains attachments such as insider information personnel registration forms, insider trading prohibition notices, and major event progress memorandums. There are no financial statements, earnings data, or investor presentations. The document is a regulatory compliance and governance-related internal policy document, not a financial report or announcement. It does not fit into categories like Annual Report, Earnings Release, or Call Transcript. It is best classified under Regulatory Filings (RNS) as it is a compliance document related to insider information management and disclosure rules, referencing relevant laws and stock exchange rules but not constituting a financial report or announcement itself.
2025-08-26 Chinese
募集资金使用管理制度（2025年8月）
Capital/Financing Update Classification · 95% confidence The document is titled '募集资金使用管理制度' which translates to 'Fundraising Capital Usage Management System'. It details the rules, procedures, and governance related to the management, storage, and use of funds raised by the company through securities issuance. The content includes regulatory references, internal controls, supervisory responsibilities, and reporting requirements related to the use of raised capital. There is no indication that this is an announcement or a brief summary; rather, it is a detailed internal policy document. It does not contain financial statements or earnings data, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a presentation, call transcript, or voting result. It is a governance-related document focused on capital management and compliance with fundraising regulations. Therefore, the most appropriate classification is Capital/Financing Update (CAP), as it relates to the management and use of capital raised by the company.
2025-08-26 Chinese
互动易平台信息发布及回复内部审核制度（2025年8月）
Governance Information Classification · 95% confidence The document is a detailed internal policy titled '互动易平台信息发布及回复内部审核制度' (Internal Review System for Information Release and Response on the Interactive Platform) issued by Harbin Yuheng Pharmaceutical Co., Ltd. It outlines rules and procedures for communication with investors via the Shenzhen Stock Exchange's interactive platform. The content focuses on governance, compliance with disclosure regulations, and internal management of investor relations communications. There are no financial statements, earnings data, audit results, or announcements of voting or capital changes. The document is a governance-related internal policy rather than a report or announcement. Therefore, the most appropriate classification is Governance Information (CGR). The document length is 2311 characters, which is relatively short but contains substantive governance content, not just an announcement or certification.
2025-08-26 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.